REFERENCES
1. Loducca SVL, Mantesso A, de Oliveira EMF, de Araújo VC. Intraosseous rhabdomyosarcoma of the mandible: a case report. Int J Surg Pathol . 2003;11(1):57-60. doi:10.1177/106689690301100115
2. Soleimani VD, Rudnicki MA. New insights into the origin and the genetic basis of rhabdomyosarcomas. Cancer Cell . 2011;19(2):157-159. doi:10.1016/j.ccr.2011.01.044
3. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics . 2010;26(5):589-595. doi:10.1093/bioinformatics/btp698
4. Cibulskis K, Lawrence MS, Carter SL, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples.Nat Biotechnol . 2013;31(3):213-219. doi:10.1038/nbt.2514
5. Kim S, Scheffler K, Halpern AL, et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat Methods . 2018;15(8):591-594. doi:10.1038/s41592-018-0051-x
6. Chapman B, Kirchner R, Pantano L, et al. bcbio/bcbio-nextgen: Published online April 14, 2021. doi:10.5281/zenodo.4686097
7. Koboldt DC, Zhang Q, Larson DE, et al. VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing.Genome Res . 2012;22(3):568-576. doi:10.1101/gr.129684.111
8. Kandoth C, Gao J, qwangmsk, et al. mskcc/vcf2maf: vcf2maf v1.6.16. Published online February 27, 2018. doi:10.5281/zenodo.1185418
9. Nakken S, Fournous G, Vodák D, Aasheim LB, Myklebost O, Hovig E. Personal Cancer Genome Reporter: variant interpretation report for precision oncology. Bioinformatics . doi:10.1093/bioinformatics/btx817
10. Quinlan MP, Settleman J. Isoform-specific ras functions in development and cancer. Future Oncol . 2009;5(1):105-116. doi:10.2217/14796694.5.1.105
11. Stolze B, Reinhart S, Bulllinger L, Fröhling S, Scholl C. Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines. Sci Rep . 2015;5:8535. doi:10.1038/srep08535
12. Pakneshan S, Salajegheh A, Anthony Smith R, King-Yin Lam A. Clinicopathological relevance of BRAF mutations in human cancer.Pathology (Phila) . 2013;45(4):346-356. doi:10.1097/PAT.0b013e328360b61d
13. Mercer KE, Pritchard CA. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta BBA - Rev Cancer . 2003;1653(1):25-40. doi:10.1016/S0304-419X(03)00016-7
14. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature . 2002;417(6892):949-954. doi:10.1038/nature00766
15. Tomei S, Bedognetti D, De Giorgi V, et al. The immune‐related role of BRAF in melanoma. Mol Oncol . 2015;9(1):93-104. doi:10.1016/j.molonc.2014.07.014
16. Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.Cell . 2010;140(2):209-221. doi:10.1016/j.cell.2009.12.040
17. Yao Z, Torres NM, Tao A, et al. BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. Cancer Cell . 2015;28(3):370-383. doi:10.1016/j.ccell.2015.08.001
18. Yao Z, Yaeger R, Rodrik-Outmezguine VS, et al. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.Nature . 2017;548(7666):234-238. doi:10.1038/nature23291
19. Kordes M, Röring M, Heining C, et al. Cooperation of BRAFF595L and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling. Leukemia . 2016;30(4):937-946. doi:10.1038/leu.2015.319
20. Yaeger R, Kotani D, Mondaca S, et al. Response to Anti-EGFR Therapy in Patients with BRAF non-V600–Mutant Metastatic Colorectal Cancer.Clin Cancer Res . 2019;25(23):7089-7097. doi:10.1158/1078-0432.CCR-19-2004
21. Franovic A, Miller N, Severson P, et al. The next-generation pan-RAF inhibitor, KIN-2787, is active in class II and class III BRAF mutant models. J Clin Oncol . 2021;39(15_suppl):3116-3116. doi:10.1200/JCO.2021.39.15_suppl.3116